Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05206942 · ClinicalTrials.gov registry record · NA
Serial Ultrasound of Solid Tumor Lesions to Detect Early Response to Cancer Immunotherapy
A NA study of Solid Tumor, sponsored by Stanford University.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05206942: Recruiting NA study of Solid Tumor, sponsored by Stanford University.
NCT05206942 is a NA study of Solid Tumor that is actively recruiting participants, run by Stanford University. The registered enrollment target is 30 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05206942, a NA study of Solid Tumor, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Primary objective is to assess whether changes in quantitative tumor perfusion parameters after 3 weeks of treatment, as measured by CEUS, can predict initial objective response to therapy, defined by current standard-of-care Secondary objectives are to evaluate if there is an optimal ultrasound imaging modality (CEUS or conventional power Doppler or LEAD ultrasound) or optimal time point to predict initial objective response and to assess the correlation of tumor perfusion parameters with change in overall tumor burden, change in diameter on a per-lesion basis, and with 12-month progression-free survival (PFS).
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Doppler ultrasound
- DIAGNOSTIC_TEST Long Ensemble Angular-coherence Doppler [LEAD] ultrasound
- DIAGNOSTIC_TEST Contrast-enhanced ultrasound (CEUS)
Study Locations (1)
California
- Stanford - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-03-21 |
| Est. Completion | 2026-02-28 |
| Phase | NA |
What NCT05206942 shows while recruiting
NCT05206942 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 3 interventions - of which Doppler ultrasound is the first listed.
NCT05206942 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05206942 about?
NCT05206942 is a clinical study titled "Serial Ultrasound of Solid Tumor Lesions to Detect Early Response to Cancer Immunotherapy". Primary objective is to assess whether changes in quantitative tumor perfusion parameters after 3 weeks of treatment, as measured by CEUS, can predict initial objective response to therapy, defined by current standard-of-care Secondary objectives are to evaluate if there is an optimal ultrasound im...
What is the current status of trial NCT05206942?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2022-03-21. Estimated completion is 2026-02-28.
What conditions does trial NCT05206942 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT05206942?
The interventions under investigation include: Doppler ultrasound (DIAGNOSTIC_TEST), Long Ensemble Angular-coherence Doppler [LEAD] ultrasound (DIAGNOSTIC_TEST), Contrast-enhanced ultrasound (CEUS) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05206942?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05206942 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05206942's enrollment target sits among peer trials
30 156th of 196 higher than 36 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
RECRUITING · NA
-
Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy
RECRUITING · NA
-
Implementation of an Oral Chemotherapy Adherence Intervention
RECRUITING · NA
-
High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations With Organ Specific Toxicity Analysis
RECRUITING · NA
-
Psychotherapy Intervention for Latinos With Adv Cancer
RECRUITING · NA
-
DESCANSO, a Mental Health Intervention for Depression, Insomnia, and Fatigue Symptoms in Latino People With Cancer
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI